Money-back guarantee may be new model in pharma marketing

Share this article:
Money-back guarantees could be the next big thing in pharmaceutical marketing, according to a recent medical journal article.
Professor Claus Moldrup of the Danish University of Pharmaceutical Sciences, Copenhagen, wrote in the British Medical Journal (BMJ) that a system of only paying for a drug if it works would be good news for manufacturers, patients and healthcare funders alike.
A money-back approach would tackle prescription problems such as wrong drug choice, genetic factors and interaction with other treatments, by forcing drug companies to ensure that the right drug gets to the right patient, Moldrup explained.
"A no-cure, no-pay strategy creates a win-win situation for the authorities as well as the drug industry, and thus patients, because in a competitive environment only the best drugs will win," he wrote in the BMJ article.
Some companies have already tried the idea.
Last year, Novartis offered U.S. patients their money back if they did not see a reduction in high blood pressure after using its hypertension drugs Diovan and Lotrel.
A Novartis spokesman told Reuters the program had been successful in driving an increase in prescriptions for its medicines.
Other companies, which have tried the concept, include Eli Lilly, which last July offered to pay for a competing product if men were not satisfied with its erectile dysfunction (ED) drug Cialis.
Meanwhile, Bayer launched a refund for in Denmark for men not satisfied with its ED drug Levitra.
"Now that drug representatives' access to doctors is being limited, and doctors are increasingly reluctant to accept direct marketing initiatives, the pharmaceutical industry will have to start considering alternative business models," Moldrup said in a Reuters report.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.